Effective treatment of multiple myeloma: A Synthesis of Findings from 133 Studies

  1. Home
  2. Effective treatment of multiple myeloma
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of multiple myeloma: A Synthesis of Findings from 133 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of multiple myeloma: A Synthesis of Findings from 133 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Multiple myeloma (MM) is a cancer of plasma cells, which are white blood cells that make antibodies. MM can cause a variety of symptoms, including bone pain, fatigue, and infections. Treatment for MM has improved significantly in recent years, with new drugs and therapies being developed. This article summarizes the latest research findings on the treatment of MM and discusses their clinical significance.

The 118 study found that daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) combined therapy was superior to bortezomib, thalidomide, and dexamethasone (VTd) combined therapy in terms of response rate and progression-free survival in patients with newly diagnosed MM who were eligible for autologous stem-cell transplant (ASCT). This study suggests that daratumumab is effective in treating MM.

The 58 study compared intensive chemotherapy alone with intensive chemotherapy followed by myeloablative chemotherapy and autologous stem-cell rescue in younger patients with newly diagnosed stage II/III MM. The study found that the latter was more cost-effective. However, the study did not find significant differences in overall survival between the two treatment arms after a median follow-up of 33 months.

The 54 study explored the optimal timing of treatment for early stage MM. The study concluded that it is unclear whether it is better to start chemotherapy right after diagnosis or delay it until symptoms become obvious as the disease progresses.

The 82 study compared carfilzomib and dexamethasone combined therapy with bortezomib and dexamethasone combined therapy in patients with relapsed or refractory MM. The study found that carfilzomib and dexamethasone combined therapy was more effective. This study suggests that carfilzomib is effective in treating MM.

The 73 study conducted a meta-analysis of randomized controlled trials (RCTs) comparing myeloablative high-dose chemotherapy (HDT) followed by single autologous stem cell transplantation with standard-dose therapy (SDT) in newly diagnosed patients under 65 years old. The meta-analysis found that HDT showed some benefit in overall survival (OS) and progression-free survival (PFS), although not all RCTs confirmed this finding.

The 74 study found that bortezomib used during induction and maintenance therapy improved survival in patients with newly diagnosed MM.

The 19 study randomized responding MM patients to either stop treatment and resume therapy at relapse or continue melphalan and prednisone (MP) until relapse. The study found that time to first relapse was significantly shorter in the no-maintenance group. However, 57% of the no-maintenance group had a second response when MP was restarted. The time to final progression on MP was longer for the no-maintenance group compared to the maintenance group, but the difference was not statistically significant. Median survival was also not significantly different between the two groups.

The 100 study found that patients with ultra-high-risk smoldering multiple myeloma (SMM) should be considered for treatment as per patients with symptomatic MM, despite not having CRAB (hyperCalcemia, Renal insufficiency, Anemia, Bone disease) symptoms. Current research is investigating whether early therapeutic strategies can benefit patients with high-risk and intermediate-risk SMM.

The 120 study systematically reviewed the benefits of radiotherapy in patients with solitary plasmacytoma (SP) or multiple myeloma (MM). The study concluded that radiotherapy plays an important role in the treatment of MM and SP.

The 35 study randomized 67 patients with relapsed or resistant multiple myeloma to receive either VAD (vincristine, doxorubicin, dexamethasone) or MOD (mitozantrone, vincristine, dexamethasone). The study found that both therapies were effective, but MOD therapy had fewer side effects and was better tolerated.

The 29 study compared polychemotherapy with vincristine, melphalan, cyclophosphamide, and prednisolone to recombinant interferon-alpha 2C monotherapy in MM patients. The study found that the response rate was significantly lower in the interferon group compared to the chemotherapy group. However, the study found that interferon-alpha 2C therapy was effective in treating other blood disorders, such as thrombocythaemia.

The 105 study systematically reviewed the cost-effectiveness of transplant, conventional chemotherapy, and novel agents in MM treatment. The study found that newly developed treatment regimens are more effective, but they also cost more.

The 57 study investigated the feasibility and toxicity of adding fludarabine to the VAD-induction regimen in MM patients. The study found that adding fludarabine was feasible and may be effective by reducing the myeloma clone.

The 127 study systematically reviewed and performed a network meta-analysis on the efficacy of maintenance treatment in patients with MM. The study found that maintenance treatment can prolong survival time, but the most appropriate maintenance regimen is still controversial.

The 122 study conducted a meta-analysis to determine the efficacy and safety of ixazomib maintenance therapy for MM patients. The study found that ixazomib is an effective and safe drug for maintenance therapy.

The 107 study conducted a network meta-analysis of multiple drug combinations of bortezomib (V), lenalidomide (R), or thalidomide (T) for the first-line treatment in adults with transplant-ineligible MM. The study found that these drug combinations are effective in treating MM.

The 119 study conducted a network meta-analysis to assess the efficacy of first-line treatment options in newly diagnosed transplant-ineligible MM (TIE-MM). The study found that the optimal first-line regimen is currently undefined.

The 126 study conducted a multinomial network meta-analysis using response rates in relapsed/refractory MM (RRMM). The study found that the treatment ranking depends on the choice of outcome.

The 90 study randomized patients with newly diagnosed myeloma without intent for immediate ASCT to receive bortezomib with lenalidomide and dexamethasone or lenalidomide and dexamethasone alone. The study found that the addition of bortezomib to lenalidomide and dexamethasone improved progression-free survival and response rates.

The 130 study presented a systematic review of available data on ASCT for MM from India. The review suggested that ASCT is an effective and cost-effective treatment option for MM in resource-constrained settings.

The 62 study found that cyclophosphamide and dexamethasone combined therapy was more effective than vincristine, doxorubicin, and dexamethasone combined therapy in newly diagnosed patients receiving high-dose melphalan and ASCT. This study suggests that cyclophosphamide is effective in treating MM.

The 111 study compared the effects of low-dose and high-dose carfilzomib with dexamethasone combined therapy in patients with relapsed-refractory MM. The study found that high-dose therapy was more effective, suggesting that carfilzomib's dosage impacts its effectiveness.

The 67 study investigated the efficacy and toxicity of different bortezomib doses combined with dexamethasone in treating relapsed or refractory MM.

The 6 study found that interferon-alfa-2b therapy during the plateau phase of MM prolonged the duration of the plateau phase.

The 32 study randomized previously untreated MM patients to receive melphalan and prednisone combined therapy or melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine combined therapy. The study found that both therapies were effective but did not find significant differences in survival time.

The 21 study updated two consecutive randomized studies in previously untreated MM patients. The study compared melphalan and prednisone combined therapy with three-drug and five-drug combinations. The study concluded that melphalan and prednisone combined therapy was as effective as the other combinations.

The 113 study systematically reviewed and performed a meta-analysis on the efficacy and safety of frontline regimens for older adults with newly diagnosed MM who are ineligible for hematopoietic cell transplantation. The study found that there are many treatment options available for these patients, but it did not define the best choice.

The 106 study assessed response-adapted intensification treatment with cyclophosphamide, bortezomib, and dexamethasone (CVD) versus no intensification treatment in patients with newly diagnosed MM who had a suboptimal response to initial immunomodulatory triplet treatment.

The 60 study evaluated the safety and efficacy of bortezomib in high-risk and elderly patients with relapsed MM. The study found that bortezomib is an appropriate treatment for these patients, even though it can have side effects.

The 28 study randomized previously untreated MM patients to receive three different chemotherapy schedules. The study concluded that it was not able to determine which regimen was optimal.

The 110 study reviewed the updated evidence from clinical trials, real-life studies, and meta-analyses regarding the use of monoclonal antibodies in relapsed/refractory MM. This review concluded that monoclonal antibodies are a very effective new approach for treating MM patients.

The 5 study investigated the feasibility and efficacy of a three-phase treatment in previously untreated aggressive myeloma. This treatment consisted of induction chemotherapy, high-dose melphalan with total body irradiation supported by unpurged autologous bone marrow transplantation, and interferon-alpha maintenance treatment. The study found that this overall strategy may represent an advance in MM management.

The 45 study randomized patients with MM who were refractory or had relapsed after cyclophosphamide-prednisone therapy to receive either VAD or VMBCP therapy. The study found that both therapies were effective for salvage treatment but there was no difference in survival between the two groups.

The 9 study randomized previously untreated MM patients to receive either an additional year of VMCP or sequential hemibody radiation (HBI) following remission induction. The study found that relapse-free survival and overall survival were better with VMCP than with HBI.

The 4 study compared the response of MM patients to chlorambucil, melphalan, and azathioprine. The study found that melphalan produced more responses than the other two agents.

The 86 study reviewed the use of bortezomib in treating MM. The study concluded that bortezomib is a proteasome inhibitor that is commonly used to treat newly diagnosed and relapsed/refractory MM.

The 128 study systematically reviewed the evidence from clinical trials on early intervention for high-risk smoldering multiple myeloma (SMM). The study found that a minimal-intensity lenalidomide-based regimen was effective in delaying disease progression and improving overall survival in high-risk SMM.

The 115 study randomized patients with untreated, high-risk MM to receive bortezomib, lenalidomide, and dexamethasone with or without elotuzumab.

The 42 study evaluated the use of bisphosphonates in MM patients. The study found that bisphosphonates can reduce bone destruction and associated complications.

The 75 study randomized patients with relapsed or refractory MM to receive either bevacizumab and bortezomib combined therapy or bortezomib alone.

Treatment Summary

Treatment for MM depends on the individual patient's condition and risk factors. The 118 study found that daratumumab, bortezomib, thalidomide, and dexamethasone combined therapy was effective in newly diagnosed patients. The 58 study found that intensive chemotherapy followed by myeloablative chemotherapy and autologous stem-cell rescue was more cost-effective in younger patients. The 82 study found that carfilzomib and dexamethasone combined therapy was effective in relapsed or refractory MM. The 73 study found that myeloablative high-dose chemotherapy followed by single autologous stem cell transplantation was the standard treatment for newly diagnosed patients under 65 years old. The 74 study found that bortezomib used during induction and maintenance therapy improved survival in newly diagnosed patients. The 100 study found that early treatment was beneficial for patients with high-risk smoldering MM. The 120 study found that radiotherapy is an important part of treatment for MM and SP.

Benefits and Risks

Benefits Summary

Treatment for MM has significantly improved in recent years, with new drugs and therapies extending survival time and improving quality of life. The 118 study found that daratumumab is effective in treating MM. The 82 study found that carfilzomib is also effective in treating MM. The 74 study found that bortezomib used during induction and maintenance therapy improved survival. The 100 study found that early treatment was beneficial for patients with high-risk smoldering MM. The 120 study found that radiotherapy is an effective part of treatment.

Risk Summary

Treatment for MM has side effects. The 58 study found that stem cell transplantation is cost-effective, but it also carries risks. The 35 study found that MOD therapy had fewer side effects and was better tolerated compared to VAD therapy. The 29 study found that interferon-alpha 2C therapy is well-tolerated. The 105 study found that novel agents are more effective than conventional therapies, but they also cost more. The 57 study found that adding fludarabine to VAD-induction therapy is feasible and may be effective, but it also has risks. The 106 study found that there were different response rates depending on whether cyclophosphamide, bortezomib, and dexamethasone combined therapy was added to the initial treatment. The 60 study found that bortezomib is an appropriate treatment for high-risk and elderly patients, but it can have side effects.

Comparison of Studies

Similarities

Multiple studies show progress in the treatment of MM. Many studies demonstrate that the development of new drugs and therapies contributes to extending patient survival and improving quality of life. However, it is not clear which treatment is best. Direct comparisons are challenging as studies differ in their patient populations and assessment methods. Despite these variations, the studies highlight ongoing advancements in MM treatment development.

Differences

Multiple studies compare MM treatment options. The 118 study found that daratumumab is effective. The 82 study found that carfilzomib is effective. The 74 study found that bortezomib is effective. The 100 study found that early treatment is beneficial for patients with high-risk smoldering MM. The 120 study found that radiotherapy is effective. These studies investigate the effectiveness and side effects of individual treatment options. Direct comparison is difficult due to variations in patient populations and assessment methods. Nevertheless, these studies showcase the ongoing advancements in MM treatment development.

Consistency and Discrepancies of Results

Research on MM treatment presents some inconsistencies. For instance, the 58 study found that stem cell transplantation is cost-effective, while the 105 study found that newer drugs are more effective but also cost more. These discrepancies likely arise from differences in patient populations and assessment methods. Further research is needed to address these discrepancies.

Applying the Results to Real Life

Research findings on MM treatment offer valuable insights for clinical practice. However, it's important to note that research results cannot be directly applied to every clinical situation. The best treatment for a given patient depends on their unique condition and risk factors. Therefore, doctors must carefully evaluate each patient's situation, consider research findings, and select the optimal treatment option. Additionally, doctors must fully explain the potential side effects of treatment and ensure patient comprehension.

Current Research Limitations

Research on MM treatment is still ongoing. Many studies involve small patient populations, making it difficult to generalize findings. Moreover, variations in study designs and assessment methods can make it challenging to compare results. Furthermore, many studies lack long-term follow-up, leaving gaps in our understanding of long-term effectiveness and safety. Additional research is essential.

Future Research Directions

Future research on MM treatment should focus on the following areas: * Development of new drugs and combination therapies * Personalized medicine research * Development of therapies that improve patients' quality of life * Long-term follow-up to evaluate effectiveness and safety * Comparison and integration of different research findings to establish robust evidence

Conclusion

Treatment for MM has significantly improved in recent years with the development of new drugs and therapies that extend patient survival and improve quality of life. Despite these advancements, MM remains a challenging disease, and the development of more effective therapies is crucial. This article has summarized the latest research findings on MM treatment and discussed their clinical significance. With further research, we can expect continued improvements in MM treatment.

If you have been diagnosed with MM, you may experience anxiety and uncertainty. However, it's important to know that MM treatment options have significantly improved. Work closely with your doctor to choose the best treatment option for your situation. Early treatment can improve your prognosis.

Treatment List

Daratumumab, Bortezomib, Thalidomide, Dexamethasone, Carfilzomib, Lenalidomide, Cyclophosphamide, Fludarabine, Interferon-alpha 2C, Autologous Stem Cell Transplant, Chemotherapy, Radiotherapy

Keywords
Benefit Keywords
Improved survival (poor risk)
Objective responses
1
Higher response rates
Longer survival times
2
Multiple myeloma treatment
Tumor reduction
3
Multiple myeloma response
4
Myeloma treatment
5
Multiple myeloma treatment
6
Improved survival
Increased remission rate
7
Improved survival with VMCP for stage III patients
8
Multiple myeloma treatment
9
Similar response rates and survival
10
Increased remission rate
11
Increased response rate
12
Prognostic information
13
Improved response rate
Well tolerated
14
Improved survival
15
Improved remission rate
Increased survival
16
Myeloma treatment
17
Improved survival
18
Disease control
MP response
19
Improved survival
20
Initial response
22
Myeloma treatment
23
Improved survival
24
Myeloma treatment
25
Increased response rates
26
Improved response rates
27
Improved response rates
28
Complete remission
Improved response rate
29
Improved response rates
Improved survival
30
Increased remission rate
Increased survival
31
Myeloma treatment
33
Myeloma response
Survival increase
34
Less toxic
Similar efficacy in relapsed/resistant multiple myeloma
35
Improved survival
36
Higher glucocorticoid efficacy
Improved myeloma survival
37
Effective treatment
38
Improved survival in multiple myeloma patients
40
Effective treatment
Low toxicity
41
Improved pain
Improved performance
Prolonged survival
Reduced complications
42
Effective treatment
44
Multiple myeloma treatment
45
Improved survival for multiple myeloma
46
Effective treatment
Prolonged remission
47
Improved bone formation
Reduced bone resorption
48
Improved myeloma treatment
Reduced relapse
49
Survival prolongation
50
Multiple myeloma treatment
51
MM treatment
52
Longer TTP
Multiple myeloma treatment
53
Improved outcome in myeloma
55
Higher remission rates
56
Fludarabine for myeloma
Myeloma cell reduction
57
Improved quality of life
Improved survival
58
Improved multiple myeloma treatment
59
Extend remission
Improve survival
Increase response rate
60
Higher response rate
Improved survival
61
Faster ASCT
Rapid response
62
Improved multiple myeloma treatment
63
Improved response
Improved survival
65
Improved survival
MM remission
67
Improved myeloma treatment
68
Improved MM outcomes
69
Multiple myeloma treatment
70
MM treatment
71
Treatment of multiple myeloma
72
Improved MM treatment
73
CR improvement
MM survival improvement
OS improvement
PFS improvement
74
Treatment of multiple myeloma
75
Improved AMM treatment
76
Improved EFS
Improved OS
77
Imaging techniques
78
Improved time to progression
79
Overall response
Overall survival
Progression-free survival
Quality of life
80
Multiple myeloma treatment
81
Multiple myeloma treatment
82
Response rate
Safe
Survival
84
Multiple myeloma treatment
86
Improved response rate
Increased progression-free survival
87
MM treatment
88
Reduced infection risk
89
Better response rates
Improved PFS
90
Multiple myeloma treatment
91
Disease-free survival
Long-term survival
Treatment with new drugs
92
Multiple myeloma treatment
93
CAR T-cell therapy
MM treatment
Monoclonal antibody therapy
94
Improved progression-free survival
95
CFZ efficacy
MM treatment
96
Improved OS
Improved PFS
97
Multiple myeloma treatment
98
Improved MM treatment
99
SMM treatment
100
Improved MM treatment
101
Improved multiple myeloma treatment
102
Improved MM treatment
103
MM treatment
mCBAD regimen
104
Cost-effective transplant
Effective novel agents
105
Improved MM treatment
106
Multiple myeloma treatment
107
Improved survival
No increased neuropathy
108
Improved SMM treatment
109
Myeloma treatment
110
Myeloma treatment
Response rate
111
Multiple myeloma treatment
112
Effective tiMM regimens
Favorable toxicity profile
Improved PFS
113
Improved MM treatment
114
Multiple myeloma treatment
115
MM treatment
116
Daratumumab for multiple myeloma
118
Improved OS
Improved PFS
119
Fracture prevention
Local control of SP
Pain relief
Palliative treatment for MM
120
Carfilzomib-based treatment for multiple myeloma
121
Prolonged survival
122
SMM management
123
Improved survival
124
Treatment for EMD in MM
125
Treatment for RRMM
126
OS
PFS
127
Delaying disease progression
Improving overall survival
128
Multiple myeloma treatment
129
Cost effective
Improved survival
Reduced toxicity
130
MM treatment
131
RRMM treatment
132
Overall response rate improvement
Progression-free survival improvement
133
Risk Keywords
Poorer survival (good risk)
1
Herpes zoster
Pneumonia
3
Palliative treatment needed
13
No significant improvement
14
Short remission
Short survival
19
No survival advantage
22
Toxicity from treatment
24
Side effects
29
Hematologic toxicity
33
Cutaneous toxicity
Haematuria
Hair loss
Myelosuppression
Raised serum direct bilirubin levels
Thrombocytopenia
35
IFN maintenance ineffective
37
Side effects
38
Increased toxicity
39
Mucositis
44
Increased morbidity and mortality
46
No significant difference between maintenance groups
49
Treatment side effects
51
Unclear if chemotherapy should be started immediately or delayed
54
Poor quality of evidence
55
Limited evidence for improved survival
56
Infections
Neutropenia
57
Increased cost
58
Multiple myeloma
59
Increased adverse events
60
Central venous access
Toxicities
62
Multiple myeloma
63
Infectious fever
Treatment-associated death
67
Myeloma
68
Thalidomide side effects
71
Limited evidence
Potential bias
77
Multiple myeloma
78
Neutropenia
Peripheral neuropathy
Thrombocytopenia
79
Adverse events
80
Adverse events
81
Increased infection risk
89
Chronic graft-versus-host disease
Relapse
92
HTN
96
High-risk features
Poor prognosis
98
Increased cost of novel agents
105
Cardiotoxicity
108
Infusion-related reactions
Lymphopenia
Neutropenia
112
Frailty biomarkers needed
Increased toxicity
113
Infection risk
Neutropenia risk
Pneumonia risk
117
Progression to MM
120
Heterogeneous nature of SMM
123
Poor prognosis
125
Adverse events
Financial burden
127
Diarrhea
Pneumonia
Upper respiratory tract infections
133
Literature analysis of 133 papers
Positive Content
127
Neutral Content
4
Negative Content
2
Article Type
87
29
32
25
133
1.

Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.

Author: HarleyJ B, PajakT F, McIntyreO R, KochwaS, CooperM R, ColemanM, CuttnerJ

Improved survival (poor risk)
Objective responses
Poorer survival (good risk)

A study of 252 patients with multiple myeloma found that the BCMP regimen (melphalan, cyclophosphamide, and carmustine) was more effective than MP (oral melphalan) in achieving objective responses. However, survival was only significantly better in the poor-risk (high tumor cell load) group treated with BCMP.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

2.

Combination therapy for multiple myeloma.

Author: AlexanianR, SalmonS, BonnetJ, GehanE, HautA, WeickJ

Higher response rates
Longer survival times

A study of 462 patients with multiple myeloma found that drug combinations including vincristine given at 3-week intervals were associated with higher response rates and longer survival times. Maintenance therapy with azathioprine-prednisone or melphalan-cyclophosphamide-carmustine-prednisone did not prolong survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

3.

Remission maintenance therapy for multiple myeloma.

Author:

Multiple myeloma treatment
Tumor reduction
Herpes zoster
Pneumonia

A study of 508 patients with multiple myeloma found that adding procarbazine or vincristine to melphalan-prednisone combination therapy did not improve outcomes. Patients who responded to treatment were then randomly assigned to one of three maintenance regimens: intermittent carmustine-prednisone, continued melphalan-prednisone, or no chemotherapy. None of these maintenance regimens significantly affected relapse rates, remission duration, or survival. Continued melphalan-prednisone therapy beyond the first year did not provide additional benefits. The study suggests that exploring alternative treatment approaches, such as immunotherapy or radiotherapy, may be more effective in reducing tumor burden.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

4.

Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine.

Author:

Multiple myeloma response

A study of 73 patients with multiple myeloma compared the effectiveness of chlorambucil, melphalan, and azathioprine, all given with prednisone and fluoxymesterone. Melphalan was associated with higher response rates compared to the other two drugs. While survival curves were similar for patients with and without risk factors, blood urea nitrogen level was the only factor impacting survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

5.

Intensive combined therapy for previously untreated aggressive myeloma.

Author: AttalM, HuguetF, SchlaiferD, PayenC, LarocheM, FournieB, MazieresB, PrisJ, LaurentG

Myeloma treatment

A three-phase treatment for aggressive myeloma, including induction chemotherapy, high-dose melphalan with autologous bone marrow transplantation, and interferon alpha maintenance, resulted in a high rate of complete response (43%) and a long duration of response. Low pretreatment beta 2 microglobulin was associated with complete response.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

6.

Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.

Author: WestinJ

Multiple myeloma treatment

A study of 308 patients with multiple myeloma randomized 120 patients in a plateau phase to receive either no further treatment or continuous interferon-alfa-2b therapy. Interferon therapy significantly prolonged the plateau phase compared to no therapy, with a median plateau duration of 59 weeks versus 26 weeks. Early data suggest a lower mortality rate for patients receiving interferon.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

7.

Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.

Author: PeestD, DeicherH, ColdeweyR, LeoR, BartlR, BartelsH, BraunH J, von BroenI M, FischerJ T, GramatzkiM

Improved survival
Increased remission rate

A study of 277 patients with multiple myeloma found that VBAMDex treatment was more effective than MivP in achieving remission for stage III patients. For stage II patients with progressive disease, MivP treatment led to remission in 61% of cases. Interferon-alpha maintenance therapy was not effective in preventing relapse in stage II and III patients with stable disease. Survival rates were higher for stage II patients compared to stage III patients.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.

Author: ShimizuK, KamiyaO, HamajimaN, MizunoH, KobayashiM, HirabayashiN, TakeyamaH, KatoR, KawashimaK, NittaM

Improved survival with VMCP for stage III patients

This study compared two chemotherapy regimens for multiple myeloma: VMCP (vincristine-melphalan-cyclophosphamide-prednisolone) and CP (cyclophosphamide-prednisolone). While no significant difference was found overall, the study found that VMCP was more effective and improved survival in patients with stage III disease. This suggests that more aggressive, multi-drug chemotherapy may be a more effective treatment for patients with more advanced multiple myeloma.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

9.

Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.

Author: SalmonS E, TeshD, CrowleyJ, SaeedS, FinleyP, MilderM S, HutchinsL F, ColtmanC A, BonnetJ D, ChesonB

Multiple myeloma treatment

This study compared different chemotherapy regimens for multiple myeloma in 614 patients. The study found that initial levels of a protein called beta-2 microglobulin were the strongest predictor of survival. There was no significant difference in effectiveness or side effects between different chemotherapy schedules. A subsequent study comparing an additional year of chemotherapy to radiation therapy with additional chemotherapy found that chemotherapy resulted in significantly longer relapse-free survival and overall survival. Radiation therapy was not effective in treating patients who did not respond to initial chemotherapy. The study concludes that radiation therapy is not a suitable treatment for multiple myeloma, and that chemotherapy is a more effective option.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

10.

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.

Author: HjorthM, HellquistL, HolmbergE, MagnussonB, RödjerS, WestinJ

Similar response rates and survival

This study compared the effectiveness of two chemotherapy regimens for treating multiple myeloma: melphalan-prednisone (MP) and multi-drug chemotherapy (MDC). The study found no significant difference in response rates, survival times, or time to response between the two groups, regardless of stage. The study concludes that multi-drug chemotherapy does not offer a significant advantage over traditional melphalan-prednisone treatment for multiple myeloma.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.

Author: PeestD, DeicherH, ColdeweyR, von BroenI M, CammererU, HeinR, HoffmannL, KonyarH, KreuserE D, SelbachJ

Increased remission rate

A study of 136 patients with multiple myeloma found that VBAMDex treatment led to a higher remission rate compared to melphalan and prednisone (MP) for stage III patients. MP was used to treat stage II patients with progressive disease. The study is ongoing, and survival data are not yet available.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.

Author: BladéJ, San MiguelJ, AlcaláA, MaldonadoJ, García-CondeJ, MoroM J, Sanz SanzM A, AlonsoC, ZubizarretaA, BessesC

Increased response rate

A study of 386 patients with multiple myeloma compared MP treatment with a combination of VCMP and VBAP chemotherapy. Combination chemotherapy resulted in a higher response rate, and although no significant difference in survival was found yet, preliminary data suggest a longer survival for patients receiving combination therapy.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Prognostic factors in multiple myeloma in a population-based trial.

Author: HannisdalE, Kildahl-AndersenO, GrøttumK A, LamvikJ

Prognostic information
Palliative treatment needed

This study investigated factors that predict survival in 92 patients with multiple myeloma. The study found that older age (over 70 years), anemia, kidney problems, and bone lesions were associated with a poorer prognosis. The study also found that a staging system developed by the Medical Research Council (MRC) was a more accurate predictor of survival compared to a different staging system. The study concludes that for older patients with multiple myeloma, treatment strategies should consider the impact on quality of life.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.

Author: ScheithauerW, CortelezziA, FritzE, KührerI, PolliE, BaldiniL, LudwigH

Improved response rate
Well tolerated
No significant improvement

A study of 33 patients with multiple myeloma compared a combination of interferon-alpha-2C and VMCP chemotherapy with VMCP chemotherapy alone. The combination treatment resulted in a higher response rate and slightly longer survival, but a significant improvement in therapeutic gain was not achieved.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.

Author: OsterborgA, AhreA, BjörkholmM, BjöremanM, BrenningG, GahrtonG, GyllenhammarH, JohanssonB, JuliussonG, JärnmarkM

Improved survival

A study of 86 patients with multiple myeloma stage III comparing combination chemotherapy with intermittent oral melphalan and prednisone found no significant difference in response rates, duration of response, or survival times. However, survival was significantly shorter for patients over 65 years old who received combination therapy.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Multiple myeloma in central and northern Norway 1981-1982: a follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy.

Author: Kildahl-AndersenO, BjarkP, BondevikA, BullO, BurgessG, DehliO, HoelS, JaegerS, KvambeV, MürerF

Improved remission rate
Increased survival

A study of 92 patients with multiple myeloma compared two-drug therapy (melphalan and prednisone) with five-drug combination therapy. Both treatments were effective in achieving remission, with similar survival rates. Maintenance treatment did not significantly affect relapse rates or survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.

Author: PeestD, DeicherH, ColdeweyR, SchmollH J, SchedelI

Myeloma treatment

This study compared two chemotherapy regimens (MP and VCMP) for treating 320 patients with multiple myeloma. Both regimens achieved similar remission rates (around 72%), but patients treated with MP had significantly longer survival compared to those treated with VCMP. After achieving remission, patients were randomly assigned to receive either continued chemotherapy or no further treatment. Patients who stopped treatment relapsed earlier, but there was no difference in resistance to initial treatment or survival between the groups. The study suggests that MP therapy may be a more effective treatment for multiple myeloma than VCMP, and that while continued chemotherapy may delay relapse, it does not seem to affect long-term survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.

Author: CornwellG G, PajakT F, KochwaS, McIntyreO R, GlowienkaL P, BrunnerK, RaflaS, ColemanM, CooperM R, HendersonE

Improved survival

A study of 589 patients with multiple myeloma found that adding vincristine and prednisone to melphalan treatment significantly improved response rates and survival, but not in patients receiving a nitrosourea.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

19.

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.

Author: BelchA, ShelleyW, BergsagelD, WilsonK, KlimoP, WhiteD, WillanA

Disease control
MP response
Short remission
Short survival

This study investigated the effectiveness of continuing melphalan and prednisone (MP) treatment after remission in 185 patients with multiple myeloma. Patients were randomly assigned to either stop treatment and resume it when they relapsed or to continue treatment until relapse. The study found that patients who stopped treatment experienced relapse earlier. However, these patients were often able to achieve a second remission when MP was restarted. The study also found that patients who had a rapid initial response or a smaller reduction in M-protein levels had shorter remission durations and shorter overall survival. While the study did not show a significant difference in survival between the two groups, the findings suggest that continuing MP therapy may be beneficial in delaying relapse and potentially extending overall survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

[Induction and maintenance therapy in multiple myeloma. Results of a multicenter study].

Author: PeestD, DeicherH

Improved survival

A study of 320 patients with multiple myeloma found that MP and VCMP chemotherapy regimens were equally effective in achieving remission. However, MP-treated patients lived longer than those receiving VCMP. Maintenance treatment did not significantly improve survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : German

21.

An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study.

Author: PavlovskyS, CorradoC, SantarelliM T, SaslavskyJ, CavagnaroF, PalauM, de Tezanos PintoM, HubermanA, LeinJ M

A long-term follow-up study of two randomized trials found that melphalan and prednisone (MP) therapy was as effective as three- and five-drug combinations in treating multiple myeloma.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.

Author: CohenH J, BartolucciA A, FormanW B, SilbermanH R

Initial response
No survival advantage

This study compared the effectiveness of three different chemotherapy regimens for multiple myeloma after initial treatment: melphalan and prednisone (MP), prednisone, Adriamycin, azathioprine, and vincristine (PAIV), and no treatment until relapse. All patients received initial treatment with BCNU, cyclophosphamide, and prednisone. The study found that while all three maintenance regimens were similarly effective, there was no significant improvement in survival compared to continuous BCP or MP therapy. The study concludes that additional chemotherapy after initial remission does not significantly improve outcomes for patients with multiple myeloma.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

23.

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.

Author: DurieB G, DixonD O, CarterS, StephensR, RivkinS, BonnetJ, SalmonS E, DabichL, FilesJ C, CostanziJ J

Myeloma treatment

This study compared different chemotherapy regimens for 440 patients with multiple myeloma. The study found that a regimen alternating between VMCP and VBAP was more effective in achieving remission (54% without levamisole and 44% with levamisole) compared to VCP (28% without levamisole and 28% with levamisole). The VMCP-VBAP regimen also resulted in significantly longer survival (48 months without levamisole and 33 months with levamisole) compared to VCP (29 months without levamisole and 26 months with levamisole). The study found that adding levamisole to either regimen did not improve response rates or survival. The study concludes that the VMCP-VBAP regimen is an effective treatment for multiple myeloma, while levamisole does not appear to improve outcomes.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

24.

Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.

Author: CooperM R, McIntyreO R, PropertK J, KochwaS, AndersonK, ColemanM, KyleR A, PragerD, RaflaS, ZimmerB

Improved survival
Toxicity from treatment

A study of 615 patients with multiple myeloma found that four different IV alkylating agent regimens led to similar response rates. The sequential regimen was associated with poorer survival. Melphalan/prednisone is recommended as initial therapy.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

25.

Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy.

Author: Kildahl-AndersenO, BjarkP, BondevikA, BullO, DehliO, KvambeV, NordahlE, YtrehusK, LamvikJ

Myeloma treatment

A study of 67 patients with multiple myeloma found that both 2-drug and 5-drug combination chemotherapy regimens were effective in achieving remission and had similar survival times. Maintenance therapy did not improve outcomes.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

26.

Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.

Author: PalvaI P, AhrenbergP, Ala-HarjaK, AlmqvistA, ApajalahtiJ, HallmanH, HänninenA, IlvonenM, IsomaaB, JärvenpääE

Increased response rates

A study comparing combination chemotherapy (MOCCA) with intermittent melphalan and prednisone (MP) for multiple myeloma found that both treatments resulted in similar survival times.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

27.

Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.

Author: RiccardiA, MerliniG, MontecuccoC, DanovaM, UcciG, CassanoE, AscariE

Improved response rates

A study of 75 patients with previously untreated multiple myeloma found that melphalan and prednisone (MPH-P) were more effective in inducing remission and prolonging survival than Peptichemio, Vincristine, and prednisone (PTC-VCR-P).

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

28.

Treatment of multiple myeloma: a randomized study of three different regimens.

Author: TribaltoM, AmadoriS, CantonettiM, FranchiA, PapaG, PileriA, BoccadoroM, DammaccoF, VaccaA, CenturioniR

Improved response rates

A study of 133 patients with multiple myeloma compared three chemotherapy regimens: melphalan plus prednisone (MP), vincristine, melphalan, cyclophosphamide, and prednisone (VMCP), and a sequential regimen of Peptichemio, cyclophosphamide, and BCNU. MP and VMCP resulted in higher response rates (35% and 46%, respectively) compared to the sequential regimen (3%). However, no significant differences were observed in overall survival between the groups. The duration of remission was similar between the MP and VMCP groups, with a median of 16 months. The study suggests that adding vincristine to chemotherapy may not improve survival and that longer induction treatment (12 cycles) may be needed to better compare the effectiveness of MP and VMCP regimens.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

29.

Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.

Author: LudwigH, CortelezziA, Van CampB G, PolliE, ScheithauerW, KuzmitsR, LinkeschW, GisslingerH, SinzingerH, FritzE

Complete remission
Improved response rate
Side effects

A study of 42 patients with multiple myeloma compared chemotherapy to interferon-alpha 2C treatment. Chemotherapy resulted in a significantly higher response rate (89%) compared to interferon (43%). Patients with stage I disease had better responses than those with stage II or III. In a separate group of 11 patients with high platelet count due to other conditions, interferon achieved complete remission in 7 out of 8 patients. Interferon treatment was associated with common side effects, but these could be reduced by decreasing the dose or stopping treatment.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

30.

Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.

Author: AhreA, BjörkholmM, MellstedtH, HolmG, BrenningG, EngstedtL, GahrtonG, HällenJ, JohanssonB, JohanssonS G, KarnströmL, KillanderA, LernerR, LocknerD, LönnqvistB, SimonssonB, StalfeltA M, TernstedtB, WadmanB

Improved response rates
Improved survival

A study of 219 patients with newly diagnosed multiple myeloma found that intermittent high-dose melphalan/prednisone therapy was more effective than continuous low-dose melphalan therapy in achieving remission and improving survival, especially for stage I and II myeloma.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

31.

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.

Author: SalmonS E, HautA, BonnetJ D, AmareM, WeickJ K, DurieB G, DixonD O

Increased remission rate
Increased survival

A study of 237 patients with multiple myeloma found that alternating combination chemotherapy was more effective than melphalan-prednisone in achieving remission and improving survival. Adding levamisole to maintenance chemotherapy also improved survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

32.

A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.

Author: PavlovskyS, SaslavskyJ, Tezanos PintoM, PalmerL, CuruchetM, LeinJ M, GarayG, DragoskyM, Quiroga-MicheoE, HubermanA B

A study of 234 patients with multiple myeloma compared two treatment regimens: melphalan and prednisone (MP) versus MP plus cyclophosphamide, MeCCNU, and vincristine (MPCCV). While MPCCV showed a slightly higher response rate (70% vs 58%), the difference was not statistically significant. Similarly, the 48-month survival rates were comparable between the two groups (37% for MP and 39% for MPCCV). Both groups showed significant differences in survival based on disease stage (stage I 56%, stage II 46%, stage III 23%) and response to treatment (good response 68%, partial response 33%, no response 16%). Patients with higher creatinine levels had significantly lower survival rates (43% vs 27%). Overall, there was no significant difference in response rate or survival between the two treatment regimens.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

33.

Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.

Author: AbramsonN, LurieP, MietlowskiW L, SchillingA, BennettJ M, HortonJ

Myeloma treatment
Hematologic toxicity

This study of patients with previously untreated multiple myeloma found that BCP and AP were comparable in terms of induction response rates, remission duration, and survival. However, BCP was associated with less hematologic toxicity.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

34.

Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.

Author: CornwellG G, PajakT F, KochwaS, McIntyreO R, GlowienkaL P, BrunnerK, RaflaS, SilverR T, CooperM R, HendersonE, KyleR A, HauraniF I, CuttnerJ

Myeloma response
Survival increase

This study of 361 patients with previously untreated multiple myeloma found that oral melphalan was superior to BCNU and CCNU in producing objective responses. Melphalan also resulted in longer survival in good-risk patients. The addition of vincristine and prednisone did not significantly improve response rates or survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

35.

A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.

Author: PhillipsJ K, Sherlaw-JohnsonC, PearceR, DaviesJ M, ReillyJ T, NewlandA C, CawleyJ C

Less toxic
Similar efficacy in relapsed/resistant multiple myeloma
Cutaneous toxicity
Haematuria
Hair loss
Myelosuppression
Raised serum direct bilirubin levels
Thrombocytopenia

This study of 67 patients with relapsed or resistant multiple myeloma found that VAD and MOD had similar efficacy in achieving plateaux. VAD was associated with a longer median duration of plateaux, but also with more severe toxicity, including hair loss, thrombocytopenia, hematuria, and cutaneous toxicity.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

36.

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.

Author: PeestD, DeicherH, ColdeweyR, LeoR, BartlR, BartelsH, BraunH J, FettW, FischerJ T, GöbelB

Improved survival

In a study of 406 people with multiple myeloma, asymptomatic early-stage patients (stages I and II) were followed without treatment until disease progression. Those with symptomatic early-stage disease or stage III disease received various treatments, including melphalan and prednisone (MP), or a combination of chemotherapy drugs (VBAMDex). Response rates to treatment were higher in the VBAMDex group compared to the MP group (64% vs 43%). However, survival was similar in both groups (36 months). After achieving remission, patients were randomly assigned to receive either interferon-alpha or no maintenance treatment. The relapse rate was similar in both groups (50% after 13 months) and interferon-alpha did not improve survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

37.

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.

Author: SalmonS E, CrowleyJ J, GroganT M, FinleyP, PughR P, BarlogieB

Higher glucocorticoid efficacy
Improved myeloma survival
IFN maintenance ineffective

Higher-dose glucocorticoids were associated with higher response rates and improved survival in multiple myeloma patients. Interferon maintenance did not improve survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

38.

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Author: RiccardiA, UcciG, LuoniR, BrugnatelliS, MoraO, SpaneddaR, De PaoliA, BarbaranoL, Di StasiM, AlberioF

Effective treatment
Side effects

This study investigated the impact of treatment intensity on the outcome of multiple myeloma (MM). Patients were divided into stages based on disease severity and received different induction therapies (melphalan and prednisone (MPH-P) or combination chemotherapy). Response rates and survival times were similar regardless of the intensity of induction therapy or whether maintenance therapy was continued. While combination chemotherapy was more effective in inducing a first response, it also caused more side effects. The study concluded that MPH-P is a safe and effective first-line treatment for MM, and that delaying treatment in early stages may be possible.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

39.

Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).

Author: KeldsenN, BjerrumO W, DahlI M, DrivsholmA, EllegaardJ, GadebergO, GimsingP, GrønvoldT, HansenM M, HippeE

Increased toxicity

A study of 151 patients with multiple myeloma compared two treatment regimens: NOP (mitoxantrone, vincristine, prednisolone) and M+P (melphalan, prednisolone). While both regimens achieved similar response rates (60% for NOP, 64% for M+P), the time to progression was longer for M+P (21 months vs. 16 months) and median survival was significantly longer for the M+P group (31 months vs. 14 months). NOP was significantly more toxic, with 7 deaths due to infection and neutropenia and one death from cardiac toxicity compared to one death from infection and neutropenia in the M+P group. The study concluded that M+P is superior to NOP as primary treatment for multiple myeloma.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

40.

Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups.

Author: PeestD, ColdeweyR, DeicherH, SailerM, VykoupilC, LeoR, GeorgiiA, KarowJ, HoeppnerE, DiehlV

Improved survival in multiple myeloma patients

A study of 320 multiple myeloma patients identified factors predicting overall and tumor-related survival. A 25% reduction in tumor cell mass after primary induction chemotherapy indicated a better prognosis. Pretreatment platelet count, tumor cell morphology, and tumor cell mass were the most reliable prognostic factors. Patients with pretreatment platelet counts ≤150,000 or poorly differentiated myeloma cells had a 50% tumor-related survival of 16 months. Patients lacking both risk factors had 50% survival times of 46 months in stage III and 88 months in stage II.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

41.

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.

Author: BrugnatelliS, RiccardiA, UcciG, MoraO, BarbaranoL, PivaN, PiccininiL, BergonziC, De PaoliA, Di StasiM, RinaldiE, TrottiG, PetriniM, AscariE

Effective treatment
Low toxicity

This study compared two chemotherapy regimens for patients with advanced, previously treated multiple myeloma. Both regimens, cyclophosphamide with prednisone and interferon-alpha2b, and epirubicin with prednisone and interferon-alpha2b, showed similar effectiveness and low side effects. The overall response rate was 43%, with a median response duration of 5.9 months and a median survival of 14.1 months. These results are comparable to those achieved with more aggressive chemotherapy regimens, suggesting that these outpatient regimens may be a viable alternative.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

42.

Bisphosphonates in multiple myeloma.

Author: BerensonJ R

Improved pain
Improved performance
Prolonged survival
Reduced complications

Pamidronate was found to be effective in reducing skeletal complications in patients with Stage III multiple myeloma. Pamidronate also improved bone pain, analgesic drug use, and performance status.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

43.

Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma.

Author: RiccardiA, MoraO, BrugnatelliS, TinelliC, SpaneddaR, De PaoliA, BarbaranoL, Di StasiM, BergonziC, GiordanoM, DelfiniC, NicolettiG, RinaldiE, PiccininiL, ValentiniD, AscariE

This study examined the impact of age on survival in multiple myeloma patients treated with conventional chemotherapy. Younger patients had longer survival times compared to older patients.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

44.

[Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group].

Author: AdamZ, KrejcíM, BacovskýJ, HejlováN, KucaB, SvojgrováM, FrankováH, GumulecJ, JancaJ, VeprekK, JanuskaB, LehankaF, RezekZ, PraskacP, CahováS, VránováM, PapajíkT, KrálováE, NovotnáJ, ScudlaV, KozaV, DrbalJ, FaberE, MareschováI, HájekR

Effective treatment
Mucositis

This study evaluated a high-dose chemotherapy regimen for treating previously untreated multiple myeloma. Patients received four cycles of VAD chemotherapy, followed by a stem cell transplant after high-dose melphalan. A second transplant was considered for patients who didn't achieve remission after the first high-dose therapy. Patients were then randomized to either interferon alpha-2b maintenance or a combination of interferon alpha-2b and dexamethasone. Of the 35 patients who received the first transplant, 57% achieved complete remission. Common side effects included mucositis requiring parenteral nutrition (40%), and blood transfusions. Early mortality rate was 3%. The study is ongoing and the long-term survival data is not yet available.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : Czech

45.

VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).

Author: MineurP, MénardJ F, Le LoëtX, BernardJ F, GrosboisB, PolletJ P, AzaisI, LaporteJ P, DoyenC, De GramontA, WetterwaldM, Euller-ZieglerL, PenyA M, MonconduitM, MichauxJ L

Multiple myeloma treatment

This study compared the effectiveness of VAD (vincristine, doxorubicin, dexamethasone) and VMBCP (vincristine, BCNU, cyclophosphamide, melphalan and prednisone) as salvage treatments for multiple myeloma patients who had progressed on cyclophosphamide-prednisone therapy. Both regimens showed similar efficacy, and survival was significantly influenced by Karnofsky index and albumin levels.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

46.

Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma.

Author: AbrahamR, ChenC, TsangR, SimpsonD, MurrayC, DavidsonM, MeharchandJ, SuttonD M, CrumpR M, KeatingA, StewartA K

Improved survival for multiple myeloma
Increased morbidity and mortality

This study investigated the use of an intensified stem cell transplantation (SCT) regimen in patients with multiple myeloma (MM), utilizing escalated melphalan and fractionated total body irradiation, as well as etoposide. While this regimen increased morbidity and mortality, it did not significantly improve overall survival compared to less toxic regimens.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

47.

Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma.

Author: AlexanianR, WeberD, DimopoulosM, DelasalleK, SmithT L

Effective treatment
Prolonged remission

Interferon was found to be more effective than dexamethasone in maintaining remission in patients with multiple myeloma after initial treatment with oral melphalan and high-dose dexamethasone.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

48.

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.

Author: TerposE, PalermosJ, TsionosK, AnargyrouK, ViniouN, PapassavasP, MeletisJ, YataganasX

Improved bone formation
Reduced bone resorption

This study investigated the effects of pamidronate on markers of bone resorption, bone formation, interleukin-6 (IL-6), beta2-microglobulin, CRP, paraprotein, and disease-related pain and skeletal events in newly diagnosed patients with multiple myeloma (MM).

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

49.

[Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group].

Author: KrejcíM, HájekR, ScudlaV, BacovskýJ, IndrákK, FaberE, KozaV, SchützováM, KucaB, SumnáE, FrankováH, LehankaF, GumulecJ, StavarováY, RezekZ, PraskacP, CahováS, VránováM, VeprekK, JanuskaJ, KesslerP, PozdĕnováV, WalterováL, StefánekI, HausdorfP, MeluzínováI, NovosadováL, LeníckováS, DusekL, SyobodníkA, KrálováE, AdamZ, MayerJ, VorlícekJ

Improved myeloma treatment
Reduced relapse
No significant difference between maintenance groups

This clinical study (4W) involved 167 patients with newly diagnosed multiple myeloma. Treatment involved induction chemotherapy, stem cell mobilization, and autologous transplantation. Patients were then randomized into two groups for maintenance treatment: one received interferon alpha and the other received alternating cycles of interferon alpha and dexamethasone. Of the 113 patients evaluated after transplantation, 12% achieved complete remission, 56% achieved remission, and 21% achieved partial remission. The mortality rate during transplantation was 2.67%. There was no significant difference between the two maintenance treatment groups in terms of the time before disease relapse. The median survival has not yet been reached.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : Czech

50.

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.

Author: BladéJ, San MiguelJ F, FontanillasM, EsteveJ, MaldonadoJ, AlcaláA, BrunetS, García-CondeJ, BesalduchJ, MoroM J, Fernández-CalvoJ, CondeE, FontL, GardellaS, CarneroM, CarbonellF, MartíJ M, Hernández-MartínJ, OrtegaF, BessesC, RiberaJ M, TrujilloJ, EscuderoM L, RozmanC, EstapéJ, MontserratE

Survival prolongation

This study compared different dose intensities of chemotherapy for multiple myeloma. The long-term outcomes of 914 patients from two randomized trials were analyzed. There was no significant difference in survival between conventional doses and higher doses of chemotherapy.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

51.

[Quality of life and tolerance of maintenance therapy in patients with multiple myeloma].

Author: AdamZ, PourL, SvobodníkA, ScudlaV, SalajkaF, VytrasováM, BacovskýJ, SchützováM, KozaV, SumnáE, FrankováH, LehankaF, GumulecJ, StavarováY, CahováS, VránováM, DostálováV, KesslerP, WalterováL, MeluzínováI, SeifertováN, SlámaO, BüchlerT, KrejcíM, BencíkováV, NykodýmováV, DusekL, HájekR,

Multiple myeloma treatment
Treatment side effects

Maintenance treatment for multiple myeloma using interferon alpha or a combination of interferon alpha and dexamethasone was associated with several undesirable side effects, including vision problems, sleep disturbances, depression, and muscle and joint pain. Patients reported a lower quality of life compared to healthy individuals.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : Czech

52.

Bendamustine in the treatment of multiple myeloma: results and future perspectives.

Author: PönischWolfram, NiederwieserDietger

MM treatment

Multiple myeloma is a cancer of plasma cells that primarily affects older adults. While melphalan and prednisone have been the standard treatment for decades, with a response rate of 60% and a median survival of 36 months, bendamustine has shown promise in early trials. This study is comparing the effectiveness of bendamustine/prednisolone with the standard melphalan/prednisolone regimen in a randomized trial.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

53.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Author: SegerenChristine M, SonneveldPieter, van der HoltBronno, VellengaEdo, CroockewitAlexandra J, VerhoefGregor E G, CornelissenJan J, SchaafsmaMartijn R, van OersMarinus H J, WijermansPierre W, FibbeWim E, WittebolShulamit, SchoutenHarry C, van Marwijk KooyMarinus, BiesmaDouwe H, BaarsJoke W, SlaterRosalyn, SteijaertMonique M C, BuijtIvon, LokhorstHenk M,

Longer TTP
Multiple myeloma treatment

Intensified chemotherapy followed by myeloablative therapy and autologous stem cell rescue resulted in a higher complete remission rate and longer time to progression compared to intensified chemotherapy alone in patients with newly diagnosed multiple myeloma. However, it did not improve event-free survival or overall survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

54.

Early versus deferred treatment for early stage multiple myeloma.

Author: HeY, WheatleyK, ClarkO, GlasmacherA, RossH, DjulbegovicB

Unclear if chemotherapy should be started immediately or delayed

Early-stage multiple myeloma (MM), which affects about 20% of patients, is often symptom-free, making it less dramatic than advanced disease. The best treatment approach for these patients is unclear: whether to start chemotherapy immediately after diagnosis or wait until symptoms appear.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

55.

Management of multiple myeloma: a systematic review and critical appraisal of published studies.

Author: KumarAmbuj, LoughranThomas, AlsinaMelissa, DurieBrian G M, DjulbegovicBenjamin

Improved outcome in myeloma
Poor quality of evidence

This review of randomized studies on myeloma found that two treatment approaches have the strongest evidence for improving outcomes: high-dose chemotherapy, which appears better than conventional chemotherapy, and the use of bisphosphonates, which reduce the risk of spinal fractures. However, the overall quality of research evidence on myeloma treatment was poor, with many studies having small sample sizes, inadequate reporting, and flawed study designs. The review concludes that the quality of evidence supporting treatment recommendations for myeloma is limited and needs significant improvement.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

56.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Author: ChildJ Anthony, MorganGareth J, DaviesFaith E, OwenRoger G, BellSusan E, HawkinsKim, BrownJulia, DraysonMark T, SelbyPeter J,

Higher remission rates
Limited evidence for improved survival

High-dose chemotherapy with stem cell transplantation is a treatment option for cancer, but its effectiveness is debated. While this approach leads to higher remission rates for multiple myeloma compared to standard chemotherapy, it is unclear if it improves long-term survival.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

57.

Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study.

Author: BjörkstrandBo, RasmussenThomas, RemesKari, GruberAstrid, PelliniemiTarja-Terttu, JohnsenHans E

Fludarabine for myeloma
Myeloma cell reduction
Infections
Neutropenia

This study evaluates the toxicity and feasibility of adding fludarabine to the VAD-induction regimen for multiple myeloma (MM) and investigates its effect on the myeloma cell hierarchy. The results suggest that adding fludarabine may be clinically effective by reducing the myeloma clone.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

58.

A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.

Author: van AgthovenM, SegerenC M, BuijtI, Uyl-de GrootC A, van der HoltB, LokhorstH M, SonneveldP

Improved quality of life
Improved survival
Increased cost

This economic evaluation compares intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy and autologous stem-cell rescue in treating multiple myeloma (MM). The study found no significant differences in overall survival but suggests that myeloablative treatment may not be cost-effective after 3 years of follow-up.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

60.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Author: RichardsonPaul G, SonneveldPieter, SchusterMichael W, IrwinDavid, StadtmauerEdward A, FaconThierry, HarousseauJean-Luc, Ben-YehudaDina, LonialSagar, San MiguelJesús-F, CavenaghJamie D, AndersonKenneth C

Extend remission
Improve survival
Increase response rate
Increased adverse events

This APEX subgroup analysis compared bortezomib to high-dose dexamethasone in elderly and high-risk patients with relapsed multiple myeloma, finding that bortezomib demonstrated significant activity, improving response rates, time to progression, and survival.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

61.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Author: RichardsonPaul G, SonneveldPieter, SchusterMichael, IrwinDavid, StadtmauerEdward, FaconThierry, HarousseauJean-Luc, Ben-YehudaDina, LonialSagar, GoldschmidtHartmut, ReeceDonna, MiguelJesus San, BladéJoan, BoccadoroMario, CavenaghJamie, AlsinaMelissa, RajkumarS Vincent, LacyMartha, JakubowiakAndrzej, DaltonWilliam, BoralAnthony, EsseltineDixie-Lee, SchenkeinDavid, AndersonKenneth C

Higher response rate
Improved survival

Bortezomib is a promising treatment for relapsed multiple myeloma patients, showing longer time to progression, higher response rate, and improved survival compared to high-dose dexamethasone.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

62.

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.

Author: MellqvistUlf-Henrik, LenhoffStig, JohnsenHans E, HjorthMartin, HolmbergErik, JuliussonGunnar, TangenJon Magnus, WestinJan,

Faster ASCT
Rapid response
Central venous access
Toxicities

The study discussed the use of combined vincristine, doxorubicin, and dexamethasone (VAD) as induction therapy before autologous stem cell transplantation (ASCT) in younger patients with newly diagnosed myeloma.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

63.

Current trends in multiple myeloma management.

Author: RedzepovicJ, WeinmannG, OttI, GustR

Improved multiple myeloma treatment
Multiple myeloma

While multiple myeloma, a type of blood cancer, is usually treated to manage symptoms, many new treatment options have emerged due to research. This review summarizes non-transplant treatments for multiple myeloma, including newer medications like immunomodulatory agents, farnesyl transferase inhibitors, and apoptosis stimulators, as well as their mechanisms of action. It also includes current recommendations from different organizations on how to treat multiple myeloma. This review aims to provide a comprehensive overview of the available treatments and inform the best possible therapy for individuals.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

64.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Author: San MiguelJesús F, SchlagRudolf, KhuagevaNuriet K, DimopoulosMeletios A, ShpilbergOfer, KropffMartin, SpickaIvan, PetrucciMaria T, PalumboAntonio, SamoilovaOlga S, DmoszynskaAnna, AbdulkadyrovKudrat M, SchotsRik, JiangBin, MateosMaria-Victoria, AndersonKenneth C, EsseltineDixie L, LiuKevin, CakanaAndrew, van de VeldeHelgi, RichardsonPaul G,

This phase 3 study compared the effectiveness of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

65.

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.

Author: JagannathSundar, BarlogieBart, BerensonJames R, SiegelDavid S, IrwinDavid, RichardsonPaul G, NiesvizkyRuben, AlexanianRaymond, LimentaniSteven A, AlsinaMelissa, EsseltineDixie-Lee, AndersonKenneth C

Improved response
Improved survival

This study presents updated survival data from the CREST trial, which investigated the effectiveness of bortezomib in treating relapsed or refractory multiple myeloma. The data suggests that a starting dose of 1.3 mg/m(2) of bortezomib is preferable, while a dose of 1.0 mg/m(2) still offers significant survival benefit if a dose reduction is necessary.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

66.

Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.

Author: FonsecaRafael, RajkumarS Vincent

This study investigates the effectiveness of two new treatment strategies for multiple myeloma, a type of blood cancer: 1) using bortezomib and dexamethasone (VD) as the initial treatment, and 2) adding bortezomib to lenalidomide and dexamethasone (VRD) as the initial treatment. The study aims to determine which approach leads to better long-term control of the disease and if these new regimens can extend survival for patients with myeloma.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

67.

[Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].

Author: BaoLi, LuXi-jing, ZhangXiao-hui, HuangXiao-jun

Improved survival
MM remission
Infectious fever
Treatment-associated death

Bortezomib at a dose of 1.3 mg/m2 was more effective than 1.0 mg/m2 in treating relapsed or refractory multiple myeloma, but it also had more side effects, including infectious fever and treatment-associated death.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : Chinese

68.

Multiple myeloma: epidemiology and therapeutic options.

Author: TuscanoJoseph M

Improved myeloma treatment
Myeloma

Multiple myeloma is a cancer that is not yet curable, but treatments have improved with newer medications. Treatment is personalized based on how the disease affects each individual and how they respond to treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

69.

[Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].

Author: MitinaT A, GolenkovA K, KataevaE V, LutskaiaT D, TrifonovaE V, KlinushkinaE F

Improved MM outcomes

Bortezomib monotherapy and multidrug therapy for resistant and recurrent multiple myeloma (MM) showed immediate and long-term benefits with low toxicity.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : Russian

70.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Author: PalumboAntonio, BringhenSara, RossiDavide, CavalliMaide, LaroccaAlessandra, RiaRoberto, OffidaniMassimo, PatriarcaFrancesca, NozzoliChiara, GuglielmelliTommasina, BenevoloGiulia, CalleaVincenzo, BaldiniLuca, MorabitoFortunato, GrassoMariella, LeonardiGiovanna, RizzoManuela, FalconeAntonietta Pia, GottardiDaniela, MontefuscoVittorio, MustoPellegrino, PetrucciMaria Teresa, CicconeGiovannino, BoccadoroMario

Multiple myeloma treatment

This phase III study examined the efficacy of the four-drug combination of bortezomib-melphalan-prednisone-thalidomide (VMPT) followed by maintenance with bortezomib-thalidomide (VMPT-VT) compared with VMP treatment alone in untreated multiple myeloma patients.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

72.

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Author: PicotJ, CooperK, BryantJ, CleggA J

Treatment of multiple myeloma

Multiple myeloma (MM) is a common type of blood cancer. While it is not curable, treatment with supportive care and chemotherapy aims to extend life and improve quality of life. Most patients can't tolerate intensive treatment like high-dose chemotherapy with stem cell transplants, so they receive single or combination chemotherapy. Common combinations include an alkylating agent and a corticosteroid. More recently, drugs like thalidomide and bortezomib have been added to these combinations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

73.

Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysis.

Author: FaussnerFlorian, DempkeWolfram C M

Improved MM treatment

High-dose chemotherapy (HDT) followed by stem cell transplant is the standard treatment for younger patients with newly diagnosed multiple myeloma (MM). While some studies suggest HDT may improve survival compared to standard-dose chemotherapy (SDT), other studies haven't confirmed this. This study aimed to analyze existing data on overall survival (OS) and progression-free survival (PFS) to better understand the benefits of HDT.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

74.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Author: SonneveldPieter, Schmidt-WolfIngo G H, van der HoltBronno, El JarariLaila, BertschUta, SalwenderHans, ZweegmanSonja, VellengaEdo, BroylAnnemiek, BlauIgor W, WeiselKatja C, WittebolShulamiet, BosGerard M J, Stevens-KroefMarian, ScheidChristof, PfreundschuhMichael, HoseDirk, JauchAnna, van der VeldeHelgi, RaymakersReinier, SchaafsmaMartijn R, KerstenMarie-Jose, van Marwijk-KooyMarinus, DuehrsenUlrich, LindemannWalter, WijermansPierre W, LokhorstHenk M, GoldschmidtHartmut M

CR improvement
MM survival improvement
OS improvement
PFS improvement

Bortezomib during induction and maintenance therapy significantly improved complete response rates, progression-free survival, and overall survival in patients with newly diagnosed multiple myeloma.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

75.

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.

Author: WhiteDarrell, KassimAdetola, BhaskarBirbal, YiJing, WamstadKaren, PatonVirginia E

Treatment of multiple myeloma

While new treatments have improved outcomes for multiple myeloma, more options are needed. Bortezomib, a medication that blocks a specific cellular process, has shown effectiveness in treating multiple myeloma that hasn't responded to other therapies. This medication also inhibits the growth of new blood vessels, which is a process involved in the development of multiple myeloma.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

76.

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.

Author: WitzigT E, LaumannK M, LacyM Q, HaymanS R, DispenzieriA, KumarS, ReederC B, RoyV, LustJ A, GertzM A, GreippP R, HassounH, MandrekarS J, RajkumarS V

Improved AMM treatment

This study found that adding thalidomide to zoledronic acid treatment for asymptomatic multiple myeloma (AMM) significantly delayed progression to active myeloma. The combination therapy group (thalidomide/zoledronic acid) had a median time to progression of 2.4 years, compared to 1.2 years for those on zoledronic acid alone. The combination therapy also led to a higher response rate and a longer duration of response. These findings suggest that adding thalidomide to standard treatment may help delay the need for chemotherapy in patients with AMM.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

77.

First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.

Author: Naumann-WinterFrauke, GrebAlexander, BorchmannPeter, BohliusJulia, EngertAndreas, SchnellRoland

Improved EFS
Improved OS
Limited evidence
Potential bias

There is insufficient evidence to definitively recommend single versus tandem autologous stem cell transplantation (ASCT) as first-line treatment for symptomatic multiple myeloma (MM). Most of the available studies are limited by bias and do not incorporate current standard treatment regimens.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

78.

The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.

Author: CaersJo, WithofsNadia, HillengassJens, SimoniPaolo, ZamagniElena, HustinxRoland, BeguinYves

Imaging techniques
Multiple myeloma

Multiple myeloma is a common blood cancer that primarily affects older adults. Most people with multiple myeloma develop bone problems. While X-rays are the standard method for diagnosis, CT scans, MRIs, and PET scans are becoming more common for detecting bone issues. These advanced imaging techniques can provide information about how well treatments are working and can also help predict the course of the disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

79.

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.

Author: CookGordon, WilliamsCathy, BrownJulia M, CairnsDavid A, CavenaghJamie, SnowdenJohn A, AshcroftA John, FletcherMarie, ParrishChris, YongKwee, CavetJim, HunterHanna, BirdJenny M, ChalmersAnna, O'ConnorSheila, DraysonMark T, MorrisTreen C M,

Improved time to progression
Neutropenia
Peripheral neuropathy
Thrombocytopenia

High-dose melphalan plus salvage autologous stem-cell transplantation (ASCT) was significantly more effective than cyclophosphamide in patients with relapsed multiple myeloma eligible for intensive therapy. The median time to progression was significantly longer in the salvage ASCT group than in the cyclophosphamide group (19 months vs 11 months).

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

80.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Author: StewartA Keith, RajkumarS Vincent, DimopoulosMeletios A, MassziTamás, ŠpičkaIvan, OriolAlbert, HájekRoman, RosiñolLaura, SiegelDavid S, MihaylovGeorgi G, Goranova-MarinovaVesselina, RajnicsPéter, SuvorovAleksandr, NiesvizkyRuben, JakubowiakAndrzej J, San-MiguelJesus F, LudwigHeinz, WangMichael, MaisnarVladimír, MinarikJiri, BensingerWilliam I, MateosMaria-Victoria, Ben-YehudaDina, KukretiVishal, ZojwallaNaseem, TondaMargaret E, YangXinqun, XingBiao, MoreauPhilippe, PalumboAntonio,

Overall response
Overall survival
Progression-free survival
Quality of life
Adverse events

Adding carfilzomib to lenalidomide and dexamethasone significantly improved progression-free survival in patients with relapsed multiple myeloma. The combination had a favorable risk-benefit profile and patients reported superior health-related quality of life.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

81.

First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.

Author: KuhrKathrin, WirthDaniel, SrivastavaKunal, LehmacherWalter, HellmichMartin

Multiple myeloma treatment
Adverse events

Melphalan and prednisone plus bortezomib (VMP) and melphalan and prednisone plus thalidomide (MPT) were more effective than melphalan and prednisone (MP) in treating multiple myeloma.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

82.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Author: DimopoulosMeletios A, MoreauPhilippe, PalumboAntonio, JoshuaDouglas, PourLudek, HájekRoman, FaconThierry, LudwigHeinz, OriolAlbert, GoldschmidtHartmut, RosiñolLaura, StraubJan, SuvorovAleksandr, AraujoCarla, RimashevskayaElena, PikaTomas, GaidanoGianluca, WeiselKatja, Goranova-MarinovaVesselina, SchwarerAnthony, MinukLeonard, MassziTamás, KaramaneshtIevgenii, OffidaniMassimo, HungriaVania, SpencerAndrew, OrlowskiRobert Z, GillenwaterHeidi H, MohamedNehal, FengShibao, ChngWee-Joo,

Multiple myeloma treatment

This study compares the effectiveness of carfilzomib and dexamethasone to bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

83.

The role of tandem stem cell transplantation for multiple myeloma patients.

Author: MartinoMassimo, RecchiaAnna Grazia, FedeleRoberta, NeriSanto, VincelliIolanda Donatella, MoscatoTiziana, GentileMassimo, MorabitoFortunato

A tandem autologous stem cell transplantation (ASCT) approach should be considered for all patients with multiple myeloma (MM), but the benefit of a second ASCT in patients who are in complete remission or experience a very good partial response should be further studied.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

84.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Author: LonialSagar, WeissBrendan M, UsmaniSaad Z, SinghalSeema, ChariAjai, BahlisNizar J, BelchAndrew, KrishnanAmrita, VescioRobert A, MateosMaria Victoria, MazumderAmitabha, OrlowskiRobert Z, SutherlandHeather J, BladéJoan, ScottEmma C, OriolAlbert, BerdejaJesus, GhariboMecide, StevensDon A, LeBlancRichard, SebagMichael, CallanderNatalie, JakubowiakAndrzej, WhiteDarrell, de la RubiaJavier, RichardsonPaul G, LisbySteen, FengHuaibao, UhlarClarissa M, KhanImran, AhmadiTahamtan, VoorheesPeter M

Response rate
Safe
Survival

Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favorable safety profile.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

85.

Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?

Author: AguiarP M, LimaT M, StorpirtisS

This systematic review assessed the economic evaluations of novel agents used in multiple myeloma (MM) treatment, examining their reporting quality and the efficient use of resources in light of rising healthcare costs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

86.

Bortezomib for the treatment of multiple myeloma.

Author: ScottKathleen, HaydenPatrick J, WillAndrea, WheatleyKeith, CoyneImelda

Multiple myeloma treatment

Bortezomib, a drug that blocks the action of proteasomes (cellular machines that break down proteins), is a common treatment for multiple myeloma, a type of blood cancer. It is used both for newly diagnosed patients and for those whose disease has returned or stopped responding to other therapies. Bortezomib is often given as a single drug or combined with other treatments.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

87.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Author: BaertschMarc-Andrea, SchlenzkaJana, MaiElias K, MerzMaximilian, HillengaßJens, RaabMarc S, HoseDirk, WuchterPatrick, HoAnthony D, JauchAnna, HielscherThomas, KunzChristina, LuntzSteffen, KleinStefan, Schmidt-WolfIngo G H, GoernerMartin, Schmidt-HieberMartin, ReimerPeter, GraevenUllrich, FenkRoland, SalwenderHans, ScheidChristof, NogaiAxel, HaenelMathias, LindemannHans W, MartinHans, NoppeneyRichard, WeiselKatja, GoldschmidtHartmut

Improved response rate
Increased progression-free survival

Lenalidomide/dexamethasone has become a standard second-line treatment for relapsed multiple myeloma (MM) patients. The ReLApsE trial aims to evaluate the effectiveness of high-dose chemotherapy consolidation plus autologous stem cell transplantation after lenalidomide/dexamethasone induction and maintenance therapy compared to the standard lenalidomide/dexamethasone regimen.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

88.

Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.

Author: RamsenthalerChristina, KanePauline, GaoWei, SiegertRichard J, EdmondsPolly M, ScheyStephen A, HigginsonIrene J

MM treatment

Multiple myeloma (MM) is a type of cancer that affects the blood. While new treatments have improved survival rates, there are no comprehensive studies on the symptoms experienced by patients due to the disease itself and its treatment. This study aims to summarize the prevalence of symptoms in MM patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

89.

Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.

Author: TehBenjamin W, HarrisonSimon J, WorthLeon J, ThurskyKarin A, SlavinMonica A

Reduced infection risk
Increased infection risk

The use of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) in patients with myeloma is associated with an increased risk of infection, particularly during maintenance therapy and relapse/refractory disease. Thalidomide was associated with the lowest risk of severe infection compared to other IMiDs. While IMiDs were associated with a reduced risk of infection during induction therapy for transplant-eligible patients, PI-based therapy did not show a significant difference compared to conventional therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

90.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Author: DurieBrian G M, HoeringAntje, AbidiMuneer H, RajkumarS Vincent, EpsteinJoshua, KahanicStephen P, ThakuriMohan, ReuFrederic, ReynoldsChristopher M, SextonRachael, OrlowskiRobert Z, BarlogieBart, DispenzieriAngela

Better response rates
Improved PFS

This study examines the use of bortezomib in combination with lenalidomide and dexamethasone for treating patients with previously untreated multiple myeloma who are not candidates for immediate autologous stem-cell transplantation. The study investigates whether adding bortezomib can improve treatment outcomes.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

91.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Author: AttalMichel, Lauwers-CancesValerie, HulinCyrille, LeleuXavier, CaillotDenis, EscoffreMartine, ArnulfBertrand, MacroMargaret, BelhadjKarim, GarderetLaurent, RousselMurielle, PayenCatherine, MathiotClaire, FermandJean P, MeulemanNathalie, RolletSandrine, MaglioMichelle E, ZeytoonjianAndrea A, WellerEdie A, MunshiNikhil, AndersonKenneth C, RichardsonPaul G, FaconThierry, Avet-LoiseauHervé, HarousseauJean-Luc, MoreauPhilippe,

Multiple myeloma treatment

High-dose chemotherapy followed by a stem cell transplant has been the standard treatment for newly diagnosed multiple myeloma in adults under 65. However, promising results with a combination of lenalidomide, bortezomib, and dexamethasone (RVD) have raised questions about the role and timing of stem cell transplants in treating this type of cancer.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

92.

Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.

Author: GiacconeLuisa, EvangelistaAndrea, PatriarcaFrancesca, SorasioRoberto, PiniMassimo, Carnevale-SchiancaFabrizio, FestucciaMoreno, BrunelloLucia, ZallioFrancesco, MaffiniEnrico, OmedéPaola, BringhenSara, MordiniNicola, FaninRenato, CicconeGiovannino, BoccadoroMario, BrunoBenedetto

Disease-free survival
Long-term survival
Treatment with new drugs
Chronic graft-versus-host disease
Relapse

This study compared the long-term outcomes of two treatment strategies for newly diagnosed myeloma patients: autologous stem cell transplant (auto-SCT) followed by a nonmyeloablative allogeneic stem cell transplant (allo-SCT) or a double auto-SCT. The study found that allo-SCT patients had significantly longer overall survival and event-free survival than auto-SCT patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

93.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Author: MateosMaría-Victoria, DimopoulosMeletios A, CavoMichele, SuzukiKenshi, JakubowiakAndrzej, KnopStefan, DoyenChantal, LucioPaulo, NagyZsolt, KaplanPolina, PourLudek, CookMark, GrosickiSebastian, CrepaldiAndre, LiberatiAnna M, CampbellPhilip, ShelekhovaTatiana, YoonSung-Soo, IosavaGenadi, FujisakiTomoaki, GargMamta, ChiuChristopher, WangJianping, CarsonRobin, CristWendy, DeraedtWilliam, NguyenHuong, QiMing, San-MiguelJesus,

Multiple myeloma treatment

A combination of bortezomib, melphalan, and prednisone is a standard treatment for newly diagnosed multiple myeloma in people who can't have a stem cell transplant. Daratumumab has shown effectiveness when added to standard treatments for people whose myeloma has returned or stopped responding to other treatments.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

94.

Emerging immune targets for the treatment of multiple myeloma.

Author: SohailAtif, MushtaqAdeela, IftikharAhmad, WarraichZabih, KurtinSandra E, TennetiPavan, McBrideAli, AnwerFaiz

CAR T-cell therapy
MM treatment
Monoclonal antibody therapy

This review explores new immunotherapy approaches for multiple myeloma (MM) that are not yet approved by the US FDA. Some promising treatments include monoclonal antibodies, like isatuximab, siltuximab, and pembrolizumab, which have shown effectiveness when used in combination with other therapies. However, other antibodies used alone, such as BI-505 and siltuximab, have not shown success. Another promising approach involves CAR T-cell therapy, which uses genetically engineered immune cells to target cancer cells. Preliminary results with CAR T-cell therapy for advanced MM are very encouraging. The future of using antibodies and T-cell therapy for MM looks promising.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

95.

Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

Author: MaieseEric M, AinsworthClaire, Le MoineJean-Gabriel, AhdesmäkiOuti, BellJudith, HaweEmma

Improved progression-free survival

This systematic literature review and network meta-analysis (NMA) estimated the relative efficacy of treatments for previously treated patients with multiple myeloma (MM), examining the most efficacious therapy among newly approved therapies like daratumumab plus lenalidomide plus dexamethasone (DRd) and daratumumab plus bortezomib plus dexamethasone (DVd).

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

96.

Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.

Author: MushtaqAdeela, KapoorVikas, LatifAzka, IftikharAhmad, ZahidUmar, McBrideAli, AbrahamIvo, RiazIrbaz Bin, AnwerFaiz

CFZ efficacy
MM treatment
HTN

Standard treatment for newly diagnosed multiple myeloma often involves a combination of three drugs, including a proteasome inhibitor like bortezomib. While effective, bortezomib can cause nerve problems (peripheral neuropathy). Carfilzomib (CFZ), another proteasome inhibitor, is more selective and has fewer side effects, including a lower risk of nerve problems. Studies show that CFZ is as effective as bortezomib and has a better safety profile, suggesting that it could be used as a first-line treatment for all types of multiple myeloma. However, more research is needed to determine the best dose of CFZ.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

97.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Author: GayFrancesca, JacksonGraham, RosiñolLaura, HolsteinSarah A, MoreauPhilippe, SpadaStefano, DaviesFaith, LahuertaJuan José, LeleuXavier, BringhenSara, EvangelistaAndrea, HulinCyrille, PanzaniUgo, CairnsDavid A, Di RaimondoFrancesco, MacroMargaret, LiberatiAnna Marina, PawlynCharlotte, OffidaniMassimo, SpencerAndrew, HájekRoman, TerposEvangelos, MorganGareth J, BladéJoan, SonneveldPieter, San-MiguelJesús, McCarthyPhilip L, LudwigHeinz, BoccadoroMario, MateosMaria-Victoria, AttalMichel

Improved OS
Improved PFS

Lenalidomide maintenance is the best treatment option for newly diagnosed multiple myeloma based on progression-free survival and overall survival results.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

98.

Prognostic factors for multiple myeloma in the era of novel therapies.

Author: ZiogasDimitrios C, DimopoulosMeletios A, KastritisEfstathios

Multiple myeloma treatment
High-risk features
Poor prognosis

This article discusses high-risk features and therapeutic options for multiple myeloma (MM) patients with an impaired prognosis. Recent advancements in molecular and genetic assays, alongside novel imaging modalities, have improved our ability to identify patients with unfavorable outcomes, while new agents, especially in combination treatments, have significantly improved the natural evolution of high-risk disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

99.

Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use.

Author: ZoppellaroGiacomo, VeroneseNicola, GranzieraSerena, GobbiLaura, StubbsBrendon, CohenAlexander T

Improved MM treatment

Multiple myeloma (MM) is often complicated by venous thromboembolism, particularly during treatment with immunomodulatory drugs. This study examines the use of acetylsalicylic acid (ASA) versus low-molecular weight heparins (LMWH) for thromboprophylaxis in MM, as guidelines differ on optimal antithrombotic strategies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

101.

Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

Author: AnwerFaiz, GeeKevin Mathew, IftikharAhmad, BaigMirza, RussAtlantis Dawn, SaeedSabina, ZarMuhammad Abu, RazzaqFaryal, CarewJennifer, NawrockiSteffan, Al-KatebHussam, Cavalcante ParrNadia Nunes, McBrideAli, ValentJason, SamarasChristy

Improved MM treatment

Multiple myeloma is a complex cancer with various genetic changes that drive its progression and resistance to treatment. Researchers are identifying specific targets for new drugs, such as those that block certain pathways (RAS, BCL-2, JAK2, NF-κB, MDM2, PI3K/mTOR), or proteins (cyclin D1, MYC, FGFR3). Medications that target these pathways are already in development or being used in combination with existing treatments. A better understanding of these pathways will help develop more personalized treatments for myeloma.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

102.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.

Author: RichardsonPaul G, OriolAlbert, BeksacMeral, LiberatiAnna Marina, GalliMonica, SchjesvoldFredrik, LindsayJindriska, WeiselKatja, WhiteDarrell, FaconThierry, San MiguelJesus, SunamiKazutaka, O'GormanPeter, SonneveldPieter, RobakPawel, SemochkinSergey, ScheySteve, YuXin, DoerrThomas, BensmaineAmine, BiyukovTsvetan, PelusoTeresa, ZakiMohamed, AndersonKenneth, DimopoulosMeletios,

Improved multiple myeloma treatment

This study assesses the efficacy and safety of a triplet regimen of pomalidomide, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma who have previously received lenalidomide.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

103.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Author: SalwenderHans, BertschUta, WeiselKatja, DuerigJan, KunzChristina, BennerAxel, BlauIgor W, RaabMarc Steffen, HillengassJens, HoseDirk, HuhnStefanie, HundemerMichael, AndrulisMindaugas, JauchAnna, Seidel-GlaetzerAndrea, LindemannHans-Walter, HenselManfred, FronhoffsStefan, MartensUwe, HansenTimon, WattadMohammed, GraevenUllrich, MunderMarkus, FenkRoland, HaenelMathias, ScheidChristof, GoldschmidtHartmut

Improved MM treatment

This phase III trial (GMMG-HD6) investigates the role of elotuzumab in combination with bortezomib, lenalidomide, and dexamethasone (VRD) as induction/consolidation and lenalidomide maintenance treatment for younger patients with multiple myeloma.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

104.

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.

Author: TabchiSamer, NairRajit, KunacheewaChutima, PatelKrina K, LeeHans C, ThomasSheeba K, AminiBehrang, AhmedSairah, MehtaRohtesh S, BashirQaiser, QazilbashMuzzaffar H, WeberDonna M, OrlowskiRobert Z, AlexanianRaymond, FengLei, ManasanchElisabet E

MM treatment
mCBAD regimen

Multiple myeloma (MM) is a type of cancer that often becomes resistant to treatment in later stages. This study reports on the use of a high-dose chemotherapy regimen (mCBAD) in people newly diagnosed with MM, those with MM that has returned or stopped responding to treatment, and those with plasma cell leukemia. This regimen may be used as a bridge to stem cell transplantation or newer treatments.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

106.

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Author: JacksonGraham H, DaviesFaith E, PawlynCharlotte, CairnsDavid A, StrihaAlina, CollettCorinne, WaterhouseAnna, JonesJohn R, KishoreBhuvan, GargMamta, WilliamsCathy D, KarunanithiKamaraj, LindsayJindriska, WilsonJamie N, JennerMatthew W, CookGordon, KaiserMartin F, DraysonMark T, OwenRoger G, RussellNigel H, GregoryWalter M, MorganGareth J,

Improved MM treatment

Multiple myeloma is a complex cancer with many different forms, suggesting that multiple treatments might be needed to achieve a good response and improve outcomes. This study examined the effectiveness of intensifying treatment for newly diagnosed myeloma by adding additional chemotherapy (cyclophosphamide, bortezomib, and dexamethasone, CVD) to standard treatment (immunomodulatory medications) in patients who had a less-than-ideal response to the initial therapy.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

107.

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.

Author: PiechottaVanessa, JakobTina, LangerPeter, MonsefIna, ScheidChristof, EstcourtLise J, OcheniSunday, TheurichSebastian, KuhrKathrin, ScheckelBenjamin, AdamsAnne, SkoetzNicole

Multiple myeloma treatment

Multiple myeloma is a type of blood cancer. The main treatment for people who aren't eligible for a stem cell transplant involves a combination of medications like bortezomib, lenalidomide, or thalidomide. However, access to these medications is limited in many countries.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

108.

[Efficacy and Safety of Carfilzomib in the Treatment of Multiple Myeloma：A Systematic Evaluation].

Author: LuoTao, XiaHai-Long

Improved survival
No increased neuropathy
Cardiotoxicity

Carfilzomib significantly improves survival in multiple myeloma patients compared to traditional treatments, without increasing the incidence of peripheral neuropathy. However, the incidence of cardiotoxicity appears to be higher. The overall response rate (ORR) was 93% and the 1-year progression-free survival (PFS) rate was 93%.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : Chinese

109.

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

Author: LandgrenC Ola, ChariAjai, CohenYael C, SpencerAndrew, VoorheesPeter, EstellJane A, SandhuIrwindeep, JennerMatthew W, WilliamsCatherine, CavoMichele, van de DonkNiels W C J, BeksacMeral, MoreauPhilippe, GoldschmidtHartmut, KuppensSteven, BandekarRajesh, ClemensPamela L, NeffTobias, HeuckChristoph, QiMing, HofmeisterCraig C

Improved SMM treatment

This study investigates the use of daratumumab in patients with smoldering multiple myeloma (SMM), assessing its efficacy and safety for delaying progression to multiple myeloma (MM).

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

110.

Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses.

Author: MustoPellegrino, La RoccaFrancesco

Myeloma treatment

Monoclonal antibodies are changing the way multiple myeloma, a type of blood cancer, is treated. New antibodies targeting specific proteins on cancer cells are showing promising results, including daratumumab, isatuximab, elotuzumab, belantamab mafodotin, nivolumab, and pembrolizumab. While these treatments offer hope, careful consideration of the best combinations and potential side effects will be crucial for effective and safe management of patients in the future.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Video-Audio MediaMedia that combines video and audio. Includes movies, TV shows, and online videos.

Language : English

111.

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.

Author: AilawadhiSikander, SextonRachael, LentzschSuzanne, AbidiMuneer H, VoorheesPeter M, CohenAdam D, RohrenEric M, HeitnerStephen, KellyKevin, MacklerNiklas J, BaerDavid M, HoeringAntje, DurieBrian, OrlowskiRobert Z

Myeloma treatment
Response rate

A randomized trial comparing twice-weekly low-dose (27 mg/m2) versus twice-weekly high-dose (56 mg/m2) melphalan in multiple myeloma patients did not demonstrate a significant benefit for the high-dose regimen.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

113.

Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis.

Author: GiriSmith, AryalMadan Raj, YuHan, GrimshawAlyssa, PathakRanjan, HuntingtonScott P, DhakalBinod

Effective tiMM regimens
Favorable toxicity profile
Improved PFS
Frailty biomarkers needed
Increased toxicity

Daratumumab, Bortezomib, Melphalan, and Prednisone (SUCRA 0.960) were the most effective treatment regimen for newly diagnosed transplant-ineligible multiple myeloma (tiMM) patients. Daratumumab, lenalidomide, and dexamethasone (Dara_RD, SUCRA 0.847) were the second most effective and also had the most favorable toxicity profile.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

114.

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

Author: GoldschmidtHartmut, BaertschMarc-Andrea, SchlenzkaJana, BeckerNatalia, HabermehlChristina, HielscherThomas, RaabMarc-Steffen, HillengassJens, SauerSandra, Müller-TidowCarsten, LuntzSteffen, JauchAnna, HoseDirk, SeckingerAnja, BrossartPeter, GoernerMartin, KleinStefan, Schmidt-HieberMartin, ReimerPeter, GraevenUllrich, FenkRoland, HaenelMathias, MartinHans, LindemannHans W, ScheidChristoph, NogaiAxel, SalwenderHans, NoppeneyRichard, BesemerBritta, WeiselKatja,

Improved MM treatment

This randomized, open-label, phase III trial compares the effectiveness of a transplant arm (including high-dose chemotherapy and autologous stem cell transplantation) versus a control arm (continuous lenalidomide) for treating relapsed and/or refractory multiple myeloma (RRMM).

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

115.

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

Author: UsmaniSaad Z, HoeringAntje, AilawadhiSikander, SextonRachael, LipeBrea, HitaSandi Fredette, ValentJason, RosenzweigMichael, ZonderJeffrey A, DhodapkarMadhav, CallanderNatalie, ZimmermanTodd, VoorheesPeter M, DurieBrian, RajkumarS Vincent, RichardsonPaul G, OrlowskiRobert Z,

Multiple myeloma treatment

New treatments have improved outcomes for multiple myeloma, a type of blood cancer. However, patients with high-risk disease have a poor long-term outlook. This study aims to find the best treatment for these patients.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

116.

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review.

Author: MohyuddinGhulam Rehman, KoehnKelly, AbdallahAl-Ola, GoodmanAaron M, PrasadVinay

MM treatment

This study found that postprotocol therapies in MM RCTs are often not reported and that when they are, many patients receive no further therapy. Reporting guidelines for postprotocol therapies are needed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

117.

Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.

Author: BalmacedaNicole, AzizMuhammad, ChandrasekarViveksandeep Thoguluva, McCluneBrian, KambhampatiSuman, ShuneLeyla, AbdallahAl-Ola, AnwerFaiz, MajeedAneela, QazilbashMuzaffar, GangulySiddhartha, McGuirkJoseph, MohyuddinGhulam Rehman

Infection risk
Neutropenia risk
Pneumonia risk

Patients with multiple myeloma have a persistent risk of grade III or higher infection, pneumonia, and neutropenia throughout treatment phases, highlighting the need for strategies to mitigate infection risk.

Historical ArticleA research paper that analyzes past events and developments using primary sources and examines them from a historical perspective.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

118.

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

Author: MoreauPhilippe, HulinCyrille, PerrotAurore, ArnulfBertrand, BelhadjKarim, BenboubkerLotfi, BénéMarie C, ZweegmanSonja, CaillonHélène, CaillotDenis, CorreJill, DelforgeMichel, DejoieThomas, DoyenChantal, FaconThierry, SonntagCécile, FontanJean, MohtyMohamad, JieKon-Siong, KarlinLionel, KuhnowskiFrédérique, LambertJérôme, LeleuXavier, MacroMargaret, Orsini-PiocelleFrédérique, RousselMurielle, StoppaAnne-Marie, van de DonkNiels W C J, WuillèmeSoraya, BroijlAnnemiek, TouzeauCyrille, TiabMourad, MarolleauJean-Pierre, MeulemanNathalie, VekemansMarie-Christiane, WestermanMatthijs, KleinSaskia K, LevinMark-David, OffnerFritz, Escoffre-BarbeMartine, EveillardJean-Richard, GaridiRéda, AhmadiTahamtan, KrevvataMaria, ZhangKe, de BoerCarla, VaraSanjay, KampfenkelTobias, VanquickelbergheVeronique, VermeulenJessica, Avet-LoiseauHervé, SonneveldPieter

Daratumumab for multiple myeloma

This study compared the effects of daratumumab maintenance versus observation alone in patients with newly diagnosed multiple myeloma who were eligible for autologous stem-cell transplantation (ASCT). Previous research (CASSIOPEIA part 1) showed that daratumumab combined with other treatments led to improved outcomes.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

119.

Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis.

Author: KissSzabolcs, GedeNoémi, SoósAlexandra, HegyiPéter, NagyBettina, ImreiMarcell, CzibereBernadett, FarkasNelli, HanákLilla, SzakácsZsolt, ErössBálint, AlizadehHussain

Improved OS
Improved PFS

This Bayesian network meta-analysis identified the most effective first-line treatment for transplant-ineligible multiple myeloma (TIE-MM) patients. The results showed that daratumumab-bortezomib-melphalan-prednisone (Dara-VMP) and daratumumab-lenalidomide-dexamethasone (Dara-Rd28) were superior to other combinations regarding progression-free survival and overall survival.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

120.

[Benefits of radiotherapy for patients with solitary plasmacytoma or multiple myeloma].

Author: KönigLaila, HerfarthKlaus

Fracture prevention
Local control of SP
Pain relief
Palliative treatment for MM
Progression to MM

Radiotherapy is the primary and curative treatment option for patients with solitary plasmacytoma (SP). Radiotherapy is mainly used for palliation in patients with multiple myeloma (MM).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : German

121.

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

Author: GayFrancesca, MustoPellegrino, Rota-ScalabriniDelia, BertaminiLuca, BelottiAngelo, GalliMonica, OffidaniMassimo, ZamagniElena, LeddaAntonio, GrassoMariella, BallantiStelvio, SpadanoAntonio, CeaMichele, PatriarcaFrancesca, D'AgostinoMattia, CapraAndrea, GiulianiNicola, de FabritiisPaolo, AquinoSara, PalmasAngelo, GamberiBarbara, ZambelloRenato, PetrucciMaria Teresa, CorradiniPaolo, CavoMichele, BoccadoroMario

Carfilzomib-based treatment for multiple myeloma

This study evaluated different carfilzomib-based induction and consolidation approaches for treating newly diagnosed multiple myeloma. The current standard of care for young and fit patients is bortezomib-based induction followed by high-dose melphalan and autologous stem-cell transplantation. This study explored alternative treatment strategies involving carfilzomib and lenalidomide.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

122.

Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis.

Author: ChenHuixian, WangYongjing, ShaoChunchun, SunChenxi, ZhengChengyun

Prolonged survival

This meta-analysis examines the efficacy and safety of ixazomib maintenance therapy in patients with multiple myeloma (MM) who have relapsed or are refractory to previous treatments.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

123.

The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.

Author: OjoAdemola S, OjukwuSomtochukwu G, AsemotaJoseph, AkinyemiOluwasegun, AraoyeMojisola O, SalehMohammed, AliAhmed, SarmaRavi

SMM management
Heterogeneous nature of SMM

This systematic review summarized the current evidence regarding the management of smoldering multiple myeloma (SMM), considering the lack of consensus on the optimal treatment approach.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

124.

Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

Author: FaconThierry, San-MiguelJesús, DimopoulosMeletios A, MateosMaria-Victoria, CavoMichele, van BeekhuizenSophie, YuanZijiao, MendesJoão, LamAnnette, HeJianming, AmmannEric, KumarShaji

Improved survival

Daratumumab-containing treatments (daratumumab/lenalidomide/dexamethasone [D-Rd], daratumumab/bortezomib/melphalan/prednisone [D-VMP]) and bortezomib/lenalidomide/dexamethasone (VRd) were more effective than continuous lenalidomide/dexamethasone (Rd) for progression-free survival (PFS) and overall survival (OS) in transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

125.

Extramedullary disease in multiple myeloma: a systematic literature review.

Author: BladéJoan, BeksacMeral, CaersJo, JurczyszynArtur, von Lilienfeld-ToalMarie, MoreauPhilippe, RascheLeo, RosiñolLaura, UsmaniSaad Z, ZamagniElena, RichardsonPaul

Treatment for EMD in MM
Poor prognosis

This study explores extramedullary involvement (EMD) in multiple myeloma (MM), a rare and aggressive form of the disease. EMD is characterized by the spread of myeloma cells outside of the bone marrow. The study reviews the incidence, clinical features, treatment outcomes, and prognostic factors associated with EMD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

126.

Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome.

Author: van Beurden-TanChrissy H Y, SonneveldPieter, GrootCarin A Uyl-de

Treatment for RRMM

This meta-analysis examines the impact of treatment choice on outcomes in patients with relapsed/refractory multiple myeloma (RRMM). The study explores the importance of considering both immediate effects (response quality) and long-term benefits (progression-free survival) when comparing different treatment options.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

127.

Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.

Author: ZhiYongjin, BaoShuojing, MaoJingcheng, ChaiGufan, ZhuJianfeng, LiuChengjiang, ChenXi

OS
PFS
Adverse events
Financial burden

This network meta-analysis identified the most effective maintenance treatment for newly diagnosed multiple myeloma (NDMM) patients. Lenalidomide-carfilzomib was recommended as the best therapy for overall survival and progression-free survival, but it should be considered in light of increased adverse events and financial burden.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

128.

Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials.

Author: OjoAdemola S, AkinyemiOluwasegun, AraoyeMojisola O, AliAhmed

Delaying disease progression
Improving overall survival

A subset of individuals with smoldering myeloma (SMM) are at a high risk of progression to symptomatic myeloma. This systematic review summarized current evidence on the optimum approach to managing high-risk SMM, including minimal, moderate, and high-intensity interventions.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

129.

Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.

Author: GuXinyuan, SunChunyan, XuJuan, LinZhimei, ZhangLi, ZhengYuhuan

Multiple myeloma treatment

This systematic review and meta-analysis assessed various regimens incorporating selinexor, a drug showing promising efficacy for relapsed/refractory multiple myeloma (RRMM), to determine its optimal timing and combination with other drugs.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

130.

Autologous stem cell transplantation for multiple myeloma in the novel agent era: Systematic review of Indian data and implications for resource constrained settings.

Author: SinghSuvir, SharmaRintu, SinghJagdeep, JainKunal, PaulDavinder

Cost effective
Improved survival
Reduced toxicity

Treatment of multiple myeloma has significantly improved over the last two decades, resulting in meaningful improvement in overall and progression-free survival. While newer drugs lead to deeper and sustained responses, autologous stem cell transplantation (ASCT) remains the standard of care for all eligible patients and is ostensibly more cost-effective than continued treatment with newer agents. Despite its benefits, ASCT is underutilized in India due to concerns about cost, safety, and sporadic expertise.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

131.

Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis.

Author: LinChi-Maw, ChangLih-Chyun, ShauWen-Yi, ChenChi-Ling, YaoChi-Yuan, TienFeng-Ming

MM treatment

For people newly diagnosed with multiple myeloma (MM), a common treatment involves high-dose therapy (HDT) followed by a bone marrow transplant (ASCT). While this approach has been effective in delaying the progression of the disease, the impact on overall survival is unclear.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

132.

Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.

Author: ChenHaimin, ChenHaiqi, ZhouYan, XuWeiwei, YuJingjing, XuYao, ZhouFan

RRMM treatment

This network meta-analysis compares the effectiveness of different novel drug combinations for treating relapsed and/or refractory multiple myeloma (RRMM). Multiple myeloma is a type of blood cancer, and new treatment options have emerged for managing the disease.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

133.

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials.

Author: HuangZeng-Yi, JinXiao-Qin, LiangQi-Lian, ZhangDing-Yue, HanHan, WangZhen-Wei

Overall response rate improvement
Progression-free survival improvement
Diarrhea
Pneumonia
Upper respiratory tract infections

Daratumumab-based regimens were effective in treating relapsed/refractory multiple myeloma, improving progression-free survival, minimal residual disease, and overall response rate. However, these regimens also increased the risk of pneumonia, upper respiratory tract infections, and diarrhea.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.